South Korea’s Ministry of Food and Drug Safety (MFDS) approved Curocell Inc.’s Limcato (anbalcabtagene-autoleucel; anbal-cel) April 29 as the first homegrown CAR T-cell therapy to treat patients with advanced diffuse large B-cell lymphomas.